本帖最后由 老马 于 2013-3-13 13:43 编辑
7 Y7 G# `1 z/ j$ {
T/ C/ M. }6 u/ T4 N* ^健择（吉西他滨）+顺铂+阿瓦斯汀; S5 E0 R3 @+ l: l
Gemzar +Cisplatin + Avastin
0 B. v' F, {; e9 U5 A& U5 P8 Zhttp://annonc.oxfordjournals.org/content/21/9/1804.full' i$ E6 Q2 _# J6 D2 H7 b- U4 P
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
5 b S0 S' V# @0 s0 X! U; E0 }4 dPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 3 \" N& j0 f! I$ W4 o# T
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 4 ^) D. m2 V! s2 s" Z' d/ y1 ^
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 251)
. L# A8 c9 v0 s; x
华为网盘附件：; ^1 E- P5 K' i$ T$ d9 s2 |
【华为网盘】ava.JPG, w6 W( J6 v0 X
|
显身卡
